Business
Exercise of Options & Total Voting Rights
Poolbeg Pharma PLC has announced the issuance of 7,903,778 new ordinary shares following the exercise of options by former employees. These new shares are expected to be admitted to trading on AIM on February 3, 2026. Following this admission, the Company's total number of ordinary shares in issue and total voting rights will be 705,103,778. This figure will serve as the denominator for shareholders calculating their notification obligations under the FCA's Disclosure Guidance and Transparency Rules. Disclaimer*
About this update from Poolbeg Pharma Plc
[{"type":"text","content":"\n\n\n \nPoolbeg Pharma plc\n \nExercise of Options & Total Voting Rights\n \n27 January 2026 - Poolbeg Pharma (AIM: POLB, 'Poolbeg' or the 'Company'), a clinical-stage biopharmaceutical company with a core focus on transforming the cancer immunotherapy field, announces that it has issued and allotted a total of 7,903,778 new ordinary shares of 0.02 pence each in the capital of the Company (\"Ordinary Shares\") following the exercise of options by former employees of the Company.\n \nApplication has been made to the London Stock Exchange for the 7,903,778 new Ordinary Shares to be admitted to trading on AIM (\"Admission\") and it is expected that Admission will become effective and trading will commence at 8.00 a.m. on 3 February 2026.\n \nTotal Voting Rights\n \nAfter Admission, the total number of Ordinary Shares in issue will be 705,103,778 and the total number of voting rights will therefore be 705,103,778. This figure may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the share capital of the Company under the FCA's Disclosure Guidance and Transparency Rules.\n \n \nEnquiries\n \n\n\n\n\nPoolbeg Pharma Plc\nJeremy Skillington, CEO\nIan O'Connell, CFO\n \n\n\n+44 (0) 207 183 1499\[email protected]\n\n\n\n\nCavendish Capital Markets Ltd (NOMAD & Joint Broker)\nGeoff Nash, Trisyia Jamaludin (Corporate Finance)\nNigel Birks (Life Science Specialist Sales)\nHarriet Ward (ECM)\n \n\n\n+44 (0) 207 220 0500\n\n\n\n\nShore Capital Stockbrokers Ltd (Joint Broker)\nDavid Coaten, Harry Davies-Ball (Corporate Advisory)\nMalachy McEntyre (Corporate Broking)\n\n\n\n+44 (0) 207 408 4090\n\n\n\n\nJ&E Davy (Joint Broker)\nAnthony Farrell, Niall Gilchrist\n \n\n\n+353 (0) 1 679 6363\n\n\n\n\nOptimum Strategic Communications\nNick Bastin, Vici Rabbetts, Elena Bates\n \n\n\n+44 (0) 208 078 4357\[email protected]\n\n\n\n\n \nAbout Poolbeg Pharma plc \nPoolbeg Pharma plc (AIM: POLB) is a clinical-stage biopharmaceutical company with a core focus on transforming the cancer immunotherapy field. The Company's lead asset, POLB 001, h...